Breaking News
April 27, 2018 - Alcohol Intake May Influence Oral Microbiome Composition
April 27, 2018 - What happens to our muscles during spaceflight and when living on Mars?
April 27, 2018 - Abdominal pain should be seen as a warning sign for invasive meningococcal disease
April 26, 2018 - Mediterranean diet enhances good bacteria living in the gut
April 26, 2018 - UA researchers aim to predict and prevent fatal disease in premature babies
April 26, 2018 - Researchers develop new method for early and accurate breast cancer screening
April 26, 2018 - Cytochalasin B-induced membrane vesicles successfully tested as vector for anti-tumor drug delivery
April 26, 2018 - Hospitals lure diabetes patients with self-care courses, but costs can weigh heavily
April 26, 2018 - Common therapy options for psoriasis can help reduce coronary plaque, study shows
April 26, 2018 - Kids Are Naturally as Fit as an ‘Iron Man’
April 26, 2018 - Traditional health claims about India’s ayurvedic foods help make them big business
April 26, 2018 - Maternal binge drinking may make offspring more vulnerable to mood problems and alcohol abuse
April 26, 2018 - VA hospitals provide better quality care than other health providers
April 26, 2018 - Cytosurge develops new 3D printing method that allows scientists to manufacture tiny, complex metal components
April 26, 2018 - Detailed genetic testing of head and neck cancers could lead to more personalized treatments
April 26, 2018 - Study shows new approach to improve survival rates for patients with stage IV Wilms tumors
April 26, 2018 - Nonsurgical technique enables people with spinal cord injuries to regain use of hands
April 26, 2018 - Elective induction of labor at 39 weeks decreases risks of C-section, other complications
April 26, 2018 - Hair products used by Black women contain dozens of hazardous chemicals
April 26, 2018 - Scientists create an atlas of the human genome
April 26, 2018 - New shape of DNA found in human cells
April 26, 2018 - Researchers target telomerase for killing NRAS-mutant melanoma cells
April 26, 2018 - Scientists improve growth of 3d brain models to better understand autism, dementia, schizophrenia
April 26, 2018 - Evox Therapeutics expands into new facilities at The Oxford Science Park
April 26, 2018 - Scientists discover new method for measuring cellular age
April 26, 2018 - UNC-Chapel Hill receives new award to help improve health of North Carolinians
April 26, 2018 - Study finds no evidence of chronic wasting disease transmissibility in macaques
April 26, 2018 - Study highlights impact of early detection on skin cancer survival
April 26, 2018 - Scientists discover culprit in reducing effectiveness of insulin
April 26, 2018 - Exploiting rabies virus machinery to usher Parkinson’s disease drug directly to the brain
April 26, 2018 - ‘Rapid autopsy’ programs seek clues to cancer within hours of death
April 26, 2018 - Personalised prescriptions according to your genetics
April 26, 2018 - ECDC analysis highlights measles vaccination gaps in teenagers and young adults
April 26, 2018 - Study assesses link between cognitive function levels and crash risk among older drivers
April 26, 2018 - Researchers uncover how obesity leads to cancer initiation
April 26, 2018 - Consuming large quantities of sugar during pregnancy can affect child’s cognition, shows study
April 26, 2018 - Researchers create new tool to measure patient uncertainty for predicting hospital readmissions
April 26, 2018 - FDA Alert: Lamictal (lamotrigine): Drug Safety Communication
April 26, 2018 - Massive single-cell survey of kidney cell types reveals new paths to disease
April 26, 2018 - Cognitive behavioral therapy can help children with autism manage emotional challenges
April 26, 2018 - CU Anschutz Medical Campus receives NIH grant to speed up discovery of new treatments
April 26, 2018 - Researchers discover significant distortions in leading genetics study method
April 26, 2018 - New combination therapy could improve survival in children with high-risk neuroblastoma
April 26, 2018 - Scientists clarify casual role of oxidative stress in metabolically abnormal and healthy obesities
April 26, 2018 - Home-based exercise program found ineffective for patients with peripheral artery disease
April 26, 2018 - Surgeries performed by older surgeons have lower patient mortality rates, study reveals
April 26, 2018 - New UCLA study could elucidate certain causes of infertility and miscarriage
April 26, 2018 - Choroidal Thickness Changes in Patients With Untreated DM
April 26, 2018 - Medical chemists discover peptic ulcer treatment metallodrug effective in ‘taming’ superbugs
April 26, 2018 - UB researchers build 3D-printed, drug-filled dentures to fight against infections
April 26, 2018 - Researchers find role of iron storage gene in slowing down prostate cancer growth
April 26, 2018 - Study suggests link between regular mid-day naps and neurocognitive function in teens
April 26, 2018 - Researchers gain ground-breaking insights into how inflammatory diseases work
April 26, 2018 - Injured U.S. Vet Receives World’s First Penis/Scrotum Transplant
April 26, 2018 - Researchers find existing drug effective at preventing onset of type 1 diabetes
April 26, 2018 - MGH researchers identify risk factors for drug overdose in youth with substance use disorders
April 26, 2018 - Researchers develop new vaccine to help people overcome bath salts abuse
April 26, 2018 - Genetic signature predicts diabetes diagnosis
April 26, 2018 - Study shows link between restless legs syndrome symptoms and brain structure
April 26, 2018 - MU researchers use new techniques to fight against diabetic retinopathy
April 26, 2018 - AAE’s new practice statements aim at improving patient care
April 26, 2018 - Expression of long non-coding RNAs can result in high levels of specific proteins involved in cancer
April 26, 2018 - FDA re-examining safety of new drug approved for Parkinson’s disease psychosis
April 26, 2018 - Unanimous Positive Result of FDA Advisory Committee Meeting for First Plant-Based Pharmaceutical Cannabidiol Treatment for Seizures in Patients with Two Rare, Severe Forms of Epilepsy
April 26, 2018 - Bacteria boost antifungal drug resistance in severe childhood tooth decay
April 26, 2018 - New study affirms bedtime habits of Americans
April 26, 2018 - Hospital patients are more interested in tracking their health data, research shows
April 26, 2018 - Study shows gene variations associated with malaria risk
April 26, 2018 - Inhealthcare teams up with MSKassist to combat problems related to obesity and aging
April 26, 2018 - Caffeine during pregnancy – babies 66 percent more likely to become overweight
April 26, 2018 - FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
April 26, 2018 - Pricey dental implants often best but insurance rarely pays
April 26, 2018 - Advion’s Peak Express software now available with the expression compact mass spectrometer
April 25, 2018 - Researchers find link between pneumonia in older people and PPI prescriptions
April 25, 2018 - Alcohol damages microbiome in the mouth
April 25, 2018 - Regular soaking in hot tub improves health outlook in obese women with PCOS
April 25, 2018 - FDA Alert: Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) Devices: Letter to Health Care Providers
April 25, 2018 - Sunshine could hold clues on the timing for a severe form of heart attack, study says
April 25, 2018 - Sartorius Stedim Biotech launches mini bioreactor vessel for ambr 250 high throughput system
April 25, 2018 - Biofeedback-assisted relaxation may help children during medical procedures
Shorter Preventive TB Tx Effective for HIV+ Patients

Shorter Preventive TB Tx Effective for HIV+ Patients

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals, a 1-month course of isoniazid/rifapentine, was comparable to the lengthier usual-care regimen for rates of TB and death.
  • Note that serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant.

BOSTON — A shorter duration of preventive therapy for tuberculosis (TB) in HIV-positive individuals was comparable to the lengthier usual-care regimen for rates of TB and death, a late-breaking phase III randomized trial presented here found.

A 1-month course of isoniazid/rifapentine, an antibiotic regimen for TB prevention, was found to be safe and effective when compared with the usual 9-month course of isoniazid alone in people with HIV infection, reported Richard E. Chaisson, MD, of Johns Hopkins University in Baltimore.

Constance Benson, MD, of the University of California San Diego, who moderated the press conference at the Conference on Retroviruses and Opportunistic Infections (CROI), but was not involved in the research, characterized these findings as having “the potential to immediately change clinical practice.”

In a separate statement released by the National Institutes of Health, Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, agreed, saying that these results “offer people living with HIV who are at risk of developing active [TB] an additional, shorter-duration prevention option that is safe, effective and more convenient.”

At the press conference, Chaisson said that while prevention of TB with isoniazid is effective, “uptake has been appallingly bad.” He added that the longer the course of the therapy is, the more people stop taking it, and described “a sense of futility” among clinicians about this problem.

A shorter, 4-week course of rifapentine and isoniazid had shown promise in animal studies, the authors said, so they hypothesized it would be non-inferior to the usual 9-month standard of care. “The bottom line is,” Chaisson added, “it was.”

Participants were eligible if they were HIV-infected individuals age 13 or older with no evidence of active TB, who had either a positive TB skin or blood test (Interferon Gamma Release Assay, or IGRA) or lived in an area with a high burden of TB (prevalence ≥60/100,000 population). They were stratified by CD4-positive cell count and antiretroviral therapy (ART) use at entry.

After randomization, patients received either 300-mg isoniazid plus 450- to 600-mg rifapentine once daily for 4 weeks or 300-mg isoniazid daily for 9 months. They were then followed for 3 years after the last participant was enrolled. ART with efavirenz or nevirapine was permitted.

Overall, 1,488 patients in the intervention group and 1,498 patients in the control group were included in the analysis. More than half were women, two-thirds were black and median body mass index was 23.5. Median CD4 count was 470 cells/mm³, and half were on ART at entry. Around 20% had a positive TB skin or blood test. The primary endpoint was the incidence rate ratio of active TB, TB death, or death due to an unknown cause, and the non-inferiority margin was 1.25 per 100 person-years.

The intervention group had an incidence of 0.65 per 100 person-years and the control group had an incidence of 0.67 per 100 person-years (IRR difference 0.023, 95% CI -0.30 to 0.35).

Rates of the primary outcome were higher for patients not on ART at entry and those with a positive TB skin or blood test, but no difference between treatments was noted, the authors said. In addition, rates were higher in the intervention group among those with baseline CD4 counts of ≤250 mm3, but the difference was not statistically significant.

Serious adverse events occurred in 5.6% of patients in the intervention group and 7.1% of the controls, but the difference was not significant. The authors noted that safety was “similar” in both arms, with more hematologic toxicity in the intervention group and more liver and neurotoxicity in the control group.

Chaisson said that the study was unlikely to be replicated, but characterized this as a “large enough, clear enough answer that it can be acted upon.” He added that he hoped this therapy would be studied in people without HIV.

The next steps would be incorporating these findings into guidelines. Chaisson said that he shared his results with the World Health Organization and encouraged them to incorporate this into new guidelines, perhaps as an amendment, “as quickly as possible.”

Chaisson disclosed support from Otsuka.

Sanofi supplied study medications for this trial.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-09-03T00:00:00-0400

last updated

Tagged with:

About author

Related Articles